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of infections caused by Neisseria meningritidis 
serogroup A subgroup 111 in Africa, 1995 
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& M. Guibourdenche' 
Between 14 January and 4 April 1995 we isolated and characterized 44 meningococcal strains in Cameroon, 
Chad, Niger, and Burkina Faso; among these was the strain A:4:PI.S/clone 111-1, which was involved in the 
second meningitis pandemic. This isolate was found in the clonal form in Niger and strains of the ET-37 
complex were also found in the other three study countries, but apparently did not cause epidemics. One 
strain (Y:2a:P1.2,5 (ET-37 complex)) was isolated in January 1995 and another (A:4:P1.9) in March 1995 
in Garoua (Cameroon). Eight strains were isolated in Moundou (Chad) between January and April 1995: the 
A:4:PI.S/clone 111-1 (1 strain); members of the ET-37 complex (Y:2a:P1.2,5 (4 strains), Y:N%P1.2,5 (1 
strain), and Y:2a:-(l strain)); and serogroup X (I strain). In Niger, 31 strains were isolated between February 
and April 1995 from different regions. All were A:4:P1.9/clone 111-1; between November 1994 and April 1995 
there were 23814 cases of meningitis reported of which 2227 resulted in death. Three strains were isolated 
in Burkina Faso in April 1995: two were Y:2a:P1.2,5 (ET-37 complex) and one was A:#:Pl.S/clone 111-1. 
Thus in 1995 the epidemic and' invasive strain (A:4:P1.9/clone 111-1) responsible for the second 
pandemic was present in the four countries (Cameroon, Chad, Niger and Burkino Faso) that make up the 
area frequently affected by such epidemics and where cases are generally reported during the dry season. 
Introduction 
The second pandemic of Neisserin meningitidis infec- 
tions ( I )  involved a strain of antigenic formula 
A:4:P1.9. which was characterized as clone 111-1 by 
multilocus enzyme electrophoresis (MEE). The pan- 
demic began in China in 1983 and spread to Nepal 
and to the north of India. About 7000 cases occurred 
in August 1957 during pilgrimages to Mecca and 
Medina (2). Spread continued to various countries. 
mostly by pilgrims who carried the strain home. The 
spread was halted within a few weeks in those coun- 
tries with good health infrastructures. e.g.. the USA 
(3). England (1). and France (5). However. in other 
countries, particularly those in Africa, the epidemic 
spread (6) and cases were still being identified in 
1995. The A:4:P1.9 strain has caused epidemics not 
only in those areas often associated with meningitis 
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(the meningitis belt (7)) but also in zones well re- 
moved from such areas. 
The 4:P1.9 strain was first isolated in 1985 and 
1989 in East and Central Africa, particularly in Chad 
( 2 ) ,  Ethiopia (8). and Kenya (9) .  Subsequently, this 
strain has been found in the meningitis belt: Niger, in 
1991: Sudan. in 1993: Chad. in 1993-94: and Mali, in 
1993-94. 
In some countries in East and Central Africa, 
e.g.. Cameroon and the Central African Republic, 
there are two very different climatic zones. The 
northern zones of these two countries consist of arid 
savanna, where epidemics of meningitis are frequent 
in the dry season: the southern zones consist o€ 
wooded savanna, where epidemics are less frequent. 
although there was an epidemic of meningitis in the 
west of the Central African Republic in 1992 (IO). 
I There is an apparent association be tween climatic changes and the onset of meningitis infections. but 0 T 
the rea2ons for this are not clear. Cartwright de- I-- - .  
of meningococcal infection: a pathogenic organism, a O 
susceptible host, the influence of extrinsic environ- ,g 
mental factors, or perhaps most frequently a combi- 
nation of all three (II). 
' In 1993-94 the invasive, epidemic, pathogenic 
clone 111-1 was reported in Niger. Chad, and 8 
Cameroon. The populations of these countries are o 
scribed'three 'major risk factors for the development u ) %  
th 
J 
k3 
large, and there is therefore a subpopulation of sen- ad 
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Fig. 1. Distribution of isolates of Neisseria meningitidis A:4:P1.9/clone 111-1 and ET-37 complex strains 
in Cameroon (Garoua), Chad (Moundou), Niger, and Burkina Faso, January-April 1995. In Niger, the progression of 
the epidemic clone is illustrated by the following numbers on the map: 1 (Maradi); 2 (Dogon Douchi); 3 (Niamey); 4 
(Tillabéry); 5 (Agadez); and 6 (Zinder). 
1 ----- Rainfall (mm) 
sitive individuals (6); an epidemic of meningitis 
becomes probable if the weather becomes dry and 
cool. 
+ We report the characteristics of 4‘4 strains that 
were isolated in Cameroon, Chad, Niger, and 
Burkina Faso during the 1993-94 ‘kpidemic. The 
cases of meningitis could be divided into two groups: 
those caused by the strain A:4:P1.9/clone 111-1. and 
the rest. In Niger, strain AA:P1.9/clone 111-1 was the 
most frequently iso!ated, where it was resporkible * 
for 5815 cases. o? which 605 had died by the first 
yeek of March 1995 (12). Subsequently, the epi- 
demic has continued. Mortality has varied from 
6:6% to 18.3% according to the area and time of 
, I  
k c  year. 
- ,  
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In this article we report the distribution of 
strains of the clone 111-1 at the end of 1994 and the 
beginning of 1995 when the climatic conditions fa- 
voured the appearance of cases of meningitis. We 
also report on the presence of other meningococcal 
strains, for example, nine strains of serogroup Y and 
one of serogroup X. 
Methods 
Bacierial strains 
Clinical isolates. Strains were isolated on “chocolate 
agar” and identified bacteriologically at Centre 
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Past eu r, Ga rou a, Cam e 1-0011 ; Mound ou H os pi t a I ,  
Chad; the Nianicy Meningitis and Schistosomiasis 
Research Centre (CERMES) Niger; and thc 
Yalgado Ouedraogo Hospital, Burkina Faso. I n  
sonie cases. the serogroup was also determined 
i n  the laboratory where the strains were isolated. 
Cultures of all strains (18-24-hours old) were used to 
inoculate the transport medium described by 
Vandekerkove et al. (Z.?), incubated overnight at 
37 O C ,  and sent in secure packaging (Sanofi Diagnos- 
.tics Pasteur, Paris, France) to the Neisseria Unit, 
Institut Pasteur, Paris, France. 
Reference strains 
Caugant (18) were used for MEE. Analysis was 
carried out for 13 enzymes: malic enzyme (ME), 
glucose-6-phosphate dehydropenwe (G6P). peptidnse 
(PEP), isocitratc dehydrogenase (1 Dt-I). aconita te 
hydratase (ACO). two glutamate dehydrogenases 
(GDl and GD2). alcohol dehydrogenase (ADM). 
fumarase (FU M ) , al ka 1 ine pli os pli a tase (A L K ) . t n.o 
indophenol oxidases (1P1 a n d  IP2) and aden!-late 
kinase (ADK). The clinical isolates were classified 
by comparing their electrophoretic profiles \vitIl the 
profiles of the reference clone 111-1 and of ET-37 
complex. 
Strain storage 
Strains I" 6818, LNP 6796, and I" 12412 were 
used as references to determine Variations in th.e 
allelic profile in the ET-37 complex. 
All strains were stored both lyophilized and fro- 
zen at -gooc, as described previously (14). The 
strains concerned are shown in Tables 1 and 2. 
Bacterial iden ti fica tion 
After transportation, strains were reisolated both 
on gonococcal-meningococcal agar (G medium) Results 
(Sanofi Diagnostics Pasteur, Paris, France) and 
selective G medium containing 3 pg/ml vancomycin. Epidemiological and clinical findings 
in Garoua (northern Cameroon) on 14 January appropriate. 
lo$cal, culture. and bacteriological characteristics. meningitis had been reported in Cameroon. 
Meningococci were only successfully isolated from as described previously (14). 
two of these cases; one serogoup Y and one 
Antibacterial sensitivity serogroup A. In 1995 three groups of strains were 
The sensitivity to each of the following antibacterials received from Chad: two in January and sis in  
was determined using a standard diffusion technique March. 
Few epidemiological data are available for on G medium (Z4): amoxicillin. amoxicillin + Chad. but it appears that there have been feu cases cln vu 1 an i c acid. ampi ci 1 I i n . ce fo t a xi m e, ce ft ri ax0 n e.  
ch 1 oram p h e n ico I. erythromycin . pe fl oxaci n . pen ici I - of meningococcal meningitis in either N*Djanienu 
or Moundou. Five groups of strains were received lin G, rifampicin, spiramycin. and sulfonamides from CERMES (Niger) between February and (sulfadiazine). April 1995. The National Health Information Sys- 
tem Directorate (Public Health Ministry. Niger) 
Serogrouping reported 23813 cases of meningitis and 2227 deaths 
Rabbit sera prepared in the laboratory were used for UP to 11 April 1995. The ProPortions of the national 
slide sero;igg]utination tests, as previously described total Of cases reported in various towns in the 
(14).  In cases where there was no clehr agglutination, south of the country and the CorresPondinS mor- 
the niethod described by Vedros was usqd (15). bidity levels were as follows: Diffa (0.02%: 2.5 per 
100000); Zinder (17%; 225 per 100000): Maradi 
(24%; 320 per 100000): Dosso (16%: 300 per 
100000); Niamey (9%; 375 per 100000): and Serotyping and subtyping 
Thc wholc cell enzyme-linked immunosorbeqt Tillabery (8%; 110 per 100000). The comparable 
assay (ELISA) technique described by Poolman & data for two towns in the north were as follows: 
Ahdillahi was used tjh). Agadez (0.2%; 20 per 100000) and Tahoua (26%; 
350 per 100000). 
The first strains from Burkina Faso were sent at Multilocus enzyme electrophoresis the beginning of April 1995. Five provinces were 
'I 'hc tcchniciiics dcscribed by Selander (17) and affected: Kénédougou, Sissili, Komitenga, Sèna and 
7.-!pg/m1 co1imycin9 and pg/mi ( I 4 ) *  as The first strain of N. ,ne17i,.tgiri~is isolated 
Strains were identified by Of morpho- 1995. However, up to April 1995 on]>/ 11 cases of 
1 ,  
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Boulgou. By the end of March 1995 there were 1000 
cases and 250 deaths. 
Antibacterial sensitivity 
All the strains were sensitive to all the antibacterials 
Bacteriological findings tested other than the sulfonamides, to which they were all resistant. 
Bacteriological identification. All the strains col- 
Serotyping Iected were Gram-negative diplococci that were positive for oxidase, catalase, and the acidification of 
glucose and maltose, and negative for fructose, su- Ail the strains of serogroup A were serotype 4 and 
crose, mannitol and lactose; and they expressed a subtype P1.9 (Table l), including all the strains iso- 
gamma-glutamyltransferase. Consequently, they lated in Niger. The three serogroup Y strains were 
were identified as N. meningitidis. Y:2a:P1.2,5; Y:NT:P1.2,5; and Y:2a:- (Table 1). 
Table 1: Description of the 44 Neisseria meningitidis strains isolated in Cameroon, Chad, Niger and Burkina 
Faso from 14 January to 4 April 1995 
Country (town) Isolation date LNP No." Age Sex Antigenic formula Clone 
Niger (Niamey) 
Cameroon (Garoua) 14/01/95 
01/03/95 
Chad (Moundou) 1 410 1 I95 
1 410 1 I95 
1 1/03/95 
13/03/95 
16/03/95 
20/03/95 
23/03/95 
30/03/95 
13/02/95 
16/02/95 
16/02/95 
17/02/95 
19/02/95 
25/02/95 
25/02/95 
25/02/95 
25/02/95 
25/02/95 
26/02/95 
26/02/95 
26/02/95 
26/02/95 
26/02/95 
26/02/95 
01/03/95 
03/03/95 
03/03/95 
04/03/95 
04/03/95 
06/03/95 
07/03/95 
07!03/95 
16/03/95 
16/03/95 
17/03/95 
.., !,.' . 27/03/95 
27/03/95 
29/03/95 
Burkina Faso 04/04/95 
04/04/95 
04/04/95 
* 'iuo3195 
L 
, '  
13230 
13534 
13265 
13266 
13405 
13406 
13407 
13453 
13454 
13474 
13325 
13326 
13327 
13328 
13329 
13353 
13354 
13355 
13356 
13357 
13358 
13359 
13360 
13361 
13362 
13363 
13383 
13384 
~ 17385 
' r3386 
i 13387 
13388 
,, ,*: 13389 
13390 
13421 
13422 
13423 
13424 !: 
13465 
13467 
13463 
13460 
13459 
13457 
6 months 
9 years 
10 years 
4 years 
7 years 
11 years 
2 years 
2 months 
10 years 
11 years 
5 years 
6 years 
6 years 
15 years 
7 years 
4 years 
8 years 
6 years 
20 years 
18 years 
2 years 
12 years 
Child 
Child 
3 years 
7 years 
8 months 
2 years 
5 years 
15 yeap 
15 years * 
8 months 
12 years 
13 years 
15 years 
10 months 
6 years 
7 months 
13 years 
20 months 
1 O years 
- 
- 
- 
M 
M 
M 
F 
M 
F 
M 
M 
M 
M 
F 
F 
F 
M 
M 
F 
F 
M 
F 
F 
F 
F 
M 
M 
M 
F 
F 
M 
F 
F 
M 
M 
M 
M 
F 
F 
- 
- 
- 
- 
- 
M 
M 
F 
Y:2a:P1.2,5 
A:4:P1.9 
Y:2a:P1.2,5 
Y:2a:P1.2,5 
A:4:P1.9 
Y:2a:Pl.2,5 
X:NT:Pl.5 
Y:2a:Pl.2,5 
Y:NT:P1.2,5 
Y:2a:- 
A:4:P1.9 
A:4:P1.9 
A:4:P1.9 
A:4:P1.9 
A:4:P1.9 
A:4:P1.9 
A:4:P1.9 
A:4:P1.9 
A:4:P1.9 
A:4:P1.9 
A:4:P1.9 
A:4:P1.9 
A:4:P1.9 
A:4:P1.9 
A:4:P1.9 
A:4:P1.9 
A:4:PI .9 
A:4:P1.9 
A:4:P1.9 
A:4:P1.9 
A:4:P1.9 
A:4:P1.9 
A:4:P1.9 
A:4:P1.9 
A:4:P1.9 
A:4:P1.9 
A:4:P1.9 
A:4:P1.9 
A:4:P1.9 
A:4:P1.9 
A:4:P1.9 
Y:2a:P1.2,5 
Y:2a:P1.2,5 
A:4:P1.9 
ET-37 
111-1 
ET-37 
ET-37 
111-1 
ET-37 
ET-37 
ET-37 
ET-37 
111-1 
111-1 
111-1 
111-1 
111-1 
111-1 
111-1 
111-1 
111-1 
111-1 
111-1 
111-1 
111-1 
111-1 
111-1 
111-1 
111-1 
111-1 
111-1 
111-1 
111-1 
111-1 
111-1 
111-1 
111-1 
111-1 
111-1 
111-1 
111-1 
111-1 
111-1 
ET-37 
ET-37 
111-1 
- 
a LNP = Laboratoire des Neisseria, Institut Pasteur, Paris, France. 
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Table 2: Allelic profiles of 44 meningococcal isolates in Cameroon, Chad, Niger, and Burkina Faso (January- 
April 1995) 
-~ 
Allele at indicated enzyme locus? 
Na. of 
isolates ME G6P PEP IDH AC0 GD1 GD2 ADH FUM ALK IP1 IP2 ADK 
Clinical isolates: clone 111-1 
Cameroon 
Chad 
Niger 
Burkina Faso 
Cameroon 
Chad 
Burkina Faso 
Clinical isolates: ET-37 complex 
Control strains: ET-37 complex 
Chad, 1994 
Chad 
Other profile 
1 
1 
31 
1 
1 
6 
2 
12412 
6818 
6 796 
12538 
12451 
1 
1 4 5 6 4  1 3 2 1 8 2 3 2  
4 3 4 5 2  1 4 1 1 8 2 3 2  
4 3 4 5 2  1 4 1 1 8 2 3 2  
4 3 4 5 2 1  4 1 1 8 2 3 2  
4 3 4 5 2  1 4 1 1 8 2 3 2  
4 3 4 5 2  1 4 1 1 8 2 3 2  
4 3 ' 4 5 2  1 4 1 1 8 2 3 2  
1 4 4 8 4  1 4 2 1 3 2 3 2  
a ME = malic enzyme; G6P = glucose 6-phosphate dehydrogenase; PEP = peptidase P; IDH = isocitrate dehydrogenase; AC0 = 
aconitate hydratase; GD1 and GD2 = glutamate dehydrogenases; ADH = alcohol dehydrogenase; FUM = fumarase; ALK = alkaline 
phosphatase; IPI and IP2 = two indophenol oxidases; and ADK = adenylate kinase. 
Multilocus enzyme electrophoresis lation as single or subdivided depends both on the 
The MEE profiles are described in Table 2. All the 
strains isolated in Niger (n = 31) were clone 111-1. 
This clone was also isolated on one instance 
each in Cameroon (Garoua), Chad (Moundou), 
and Burkina Faso (Ouagadougou). The other 
Y:2a:P1.2,5 strains (one from Cameroon, four from 
Chad. and two from Burkina Faso) and the strains 
Y:NT:P1.2,5 and Y:2a:- all belonged to the ET-37 
complex. 
Discussion 
The 44 strains isolated in the four study coun- 
tries had different antigenic formulae and MEE 
profiles. 
The 31 strains isolated in Niger were apparen- 
tly identical (A:4:Pl.B/clone 111-1. .resistánt to 
sulfonamides), as assessed by the ,methods used 
in the study. By definition, a clone is a group of 
bacteria descended from a single aqses'tral cell, 
all the members of whichlhave numerous iden- 
tical properties (I):'There, may be differences in 
some of the less [stable characters between indi- 
viduals of the clone; strains of the clone III isolated! 
before the Mecca epidemic, for example, expressed 
variably the Opa protein 5h, whereas those iso- 
lated after this epidemic expressed variably the 
protein 5i (19). Thus, the description of a popu- 
power of the epidemiological markers and their 
genetic variability. More profound variations can 
also occur, as observed in 1992 in the Central 
African Republic with the re-emergence of an 
A:4:Pl.7/clone IV-1 strain responsible for a previous 
epidemic. 
The clonal structure of N. nzeningitis serogroup 
A was first described by Olyhoek et al. (20). There 
have subsequently been numerous studies of the epi- 
demics caused by this serogroup and its clonal varia- 
tions. For example, Wang et al. reported 290 strains 
that could be classified into nine groups (54 different 
patterns in total) by ME€ (21). One of these nine 
groups is the clone III that we have reported in the 
present study. These strains originated in China. 
where they are now rare. 
The subgroup III was first found in the eastern. 
then the central regions of the area of Africa covered 
by our study. Finally, the strain appeared in the west. 
north, and south. This pattern of spread is similar to 
that which we-reported in 1994'in 12 African coun- 
tries (22). 
Our findings therefore indicate that the sec- 
ond meningitis pandemic has returned to the fol- 
lowing African countries: Burkina Faso, Cameroon. 
Chad, and Niger. However, a severe epidemic has 
only developed in Niger. A large-scale vaccination 
campaign has been launched to prevent its spread: 
in developing countries, vaccination is the best 
approach to combating epidemics (23,24). 
WHO Bulletin OMS. Vol 74 1996 I as 
t 
J.-Y. Riou et al. 
Because the climatic conditions were favour- 
able, the reappearance of the strain A:-C:P1.9/ 
clone 111-1 a t  the end of 1994 resulted i n  the re- 
turn of the second pandemic. Hokirever, this sec- 
ond pandemic does not appear to extend beyond 
the meningitis belt and, except in Niger, is less 
severe than previous pandemics: the numbers of 
cases in Garoua (Cameroon). Moundou (Chad), 
and Ouagadougou (Burkina Faso) are relatively 
low. 
Serogroup Y strains were first characterized 
only recently: the strains are both members of the 
ET-37 complex (first described in 1993 by Wang 
et al. (25)) and are virulent. Over the last 10 years. 
20% of the meningococcal disease in Norway has 
been due to serogroup C strains (26). These strains 
are all similar and belong to a single clone (ET-37 
complex). Caugant has reported that the meningitis 
epidemics in the U. S. army in the 1960s and in Brazil 
and South Africa in the 1970s were due to serogroup 
C strains (26). and that these strains display substan- 
tial variability (27). 
The association of serogroup Y and with the 
antigenic formula 2a:Pl.5,2 has been described pre- 
viously (26). 
N. menii7gitidi.7 serogroup A (antigenic formula 
-F:P1.9/clonz III- 1)  is currently causins a major 
epidemic in Niger. Strains of the ET-37 coni- 
plex have also recently been found in northern 
Cameroon (Garoua), Chad (Moundou). and 
Burkina Faso (Ouagadougou). Since the 1c)SCls. the 
intervals between epidemic outbreaks of nien- 
ingitis have become both shorter and niore irre- 
3 d i i r  (38). These epidemics reach their peak after 
several weeks. but can last m a n y  months in the 
absence of mass vaccination. The kinetics of the 
levels of anti-capsular polyoside and anti-outer 
membrane pro-tein anti-bodies c i i l  affect the 
progress of the epidemic ( 6 ) .  Climatic condi- 
tions rilso contribute to its scwrity. sprcac! beins 
favoured by the dry season or period of relative 
dryness. Strain X:4:PI .g/cione I I I .  1 is strongly ini- 
plicated in this epidemic. but is not the only strain 
involved. 
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Resume 
Un retour prévisible: la deuxième 
pandémie d'infections a Neisseria 
meningitidis serogroupe A sous-groupe 111 
e n  Afrique (1995) 
Entre le 14 janvier et le 4 avril 1995, nous avons 
étudié 44 souches de méningocoques isolées dans 
quatre pays africains, et déterminé leurs caractéris- 
tiques. II s'agissait de la souche responsable de la 
deuxième pandémie (souche A:4:P1.9/clone 111-1) 
qui a émerge d'une façon prévisible, et s'est pré- 
sentée sous une forme clonale au Niger, et des 
souches assimilables au complexe ET-37 par leur 
profil en électrophorèse enzymatique multilocus, 
mais qui n'ont apparemment pas causé d'epidemie. 
Une souche Y:2a:P1.2,5 (complexe ET-37) a été 
isolée en janvier et une souche A:4:P1.9 en mars à 
Garoua (Cameroun). Huit souches ont été isolées à 
Moundou (Tchad) entre janvier et avril 1995: une 
souche A:4:P1.9/clone 111-1 , six souches appar- 
tenant au complexe ET-37 (quatre Y:Za:PI .2,5, 
une Y:NT:PI.2,5 et une Y:2a:-), et une souche de 
sérogroupe X. Au Niger, 31 souches ont été isolées 
entre février et avril 1995 dans différentes régions. 
II s'agissait dans tous les cas de souches A:4:P1.9/ 
clone 111-1. Dans ce dernier pays, entre novem- 
bre 1994 et avril 1995, on a dénombré 23 814 cas 
et 2 217 décès. Trois souches ont été isolées 
au Burkina Faso en avril 1995 : deux souches 
Y:2a:P1.2,5 (ET-37) et une souche A:4:P1.9/clone 
Ill-I * 
Ainsi en 1995, la souche épidémiogène et 
invasive responsable de la deuxième pandémie 
était présente dans quatre pays (Tchad, Niger. 
Cameroun et Burkina Faso) qui sont des pays 
fréquemment affectés par de telles épidémies 
durant la saison sèche. 
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